- Home
- NAMS vs NVAX Comparison
NAMS vs NVAX Comparison
Compare NAMS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- NVAX
- Stock Information
- Founded
- NAMS 2019
- NVAX 1987
- Country
- NAMS Netherlands
- NVAX United States
- Employees
- NAMS N/A
- NVAX N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAMS Health Care
- NVAX Health Care
- Exchange
- NAMS Nasdaq
- NVAX Nasdaq
- Market Cap
- NAMS 2.3B
- NVAX 2.0B
- IPO Year
- NAMS N/A
- NVAX 1995
- Fundamental
- Price
- NAMS $20.12
- NVAX $8.04
- Analyst Decision
- NAMS Strong Buy
- NVAX Buy
- Analyst Count
- NAMS 6
- NVAX 6
- Target Price
- NAMS $33.80
- NVAX $17.83
- AVG Volume (30 Days)
- NAMS 634.7K
- NVAX 5.8M
- Earning Date
- NAMS 11-06-2024
- NVAX 11-12-2024
- Dividend Yield
- NAMS N/A
- NVAX N/A
- EPS Growth
- NAMS N/A
- NVAX N/A
- EPS
- NAMS N/A
- NVAX N/A
- Revenue
- NAMS $33,594,000.00
- NVAX $885,193,000.00
- Revenue This Year
- NAMS N/A
- NVAX N/A
- Revenue Next Year
- NAMS N/A
- NVAX N/A
- P/E Ratio
- NAMS N/A
- NVAX N/A
- Revenue Growth
- NAMS 78.77
- NVAX N/A
- 52 Week Low
- NAMS $8.90
- NVAX $3.53
- 52 Week High
- NAMS $26.35
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- NAMS 44.60
- NVAX 35.60
- Support Level
- NAMS $19.59
- NVAX $6.81
- Resistance Level
- NAMS $25.32
- NVAX $10.39
- Average True Range (ATR)
- NAMS 1.44
- NVAX 0.65
- MACD
- NAMS -0.32
- NVAX 0.03
- Stochastic Oscillator
- NAMS 36.35
- NVAX 34.36
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.